ReNeuron Group (OTCMKTS:RNUGF) vs. Collegium Pharmaceutical (NASDAQ:COLL) Critical Contrast

Collegium Pharmaceutical (NASDAQ:COLL) and ReNeuron Group (OTCMKTS:RNUGF) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.

Volatility and Risk

Collegium Pharmaceutical has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Comparatively, ReNeuron Group has a beta of -0.63, indicating that its stock price is 163% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Collegium Pharmaceutical and ReNeuron Group, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0	1	3	2	3.17
ReNeuron Group	0	0	0	0	0.00

Collegium Pharmaceutical presently has a consensus target price of $57.50, suggesting a potential upside of 61.56%. Given Collegium Pharmaceutical’s stronger consensus rating and higher probable upside, equities analysts clearly believe Collegium Pharmaceutical is more favorable than ReNeuron Group.

Earnings and Valuation

This table compares Collegium Pharmaceutical and ReNeuron Group”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57 million	1.48	$62.87 million	$2.04	17.45
ReNeuron Group	N/A	N/A	N/A	N/A	N/A

Collegium Pharmaceutical has higher revenue and earnings than ReNeuron Group.

Profitability

This table compares Collegium Pharmaceutical and ReNeuron Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	9.41%	95.18%	16.39%
ReNeuron Group	N/A	N/A	N/A

Summary

Collegium Pharmaceutical beats ReNeuron Group on 9 of the 9 factors compared between the two stocks.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

About ReNeuron Group

ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.